Adeno-associated virus as a delivery vector for gene therapy of human diseases
Top 5 Most-Read Articles On Rare Blood Disorders In 2024
Key findings from 2024 focused on conditions like vaccine-induced immune thrombotic thrombocytopenia, immune thrombocytopenia, and hemophilia, stressing the importance of early detection and innovative therapies.
As research into rare blood disorders advances, 2024 has seen research illuminate the challenges and breakthroughs in diagnosis and treatment. Key findings focused on conditions like vaccine-induced immune thrombotic thrombocytopenia (VITT), immune thrombocytopenia (ITP), and hemophilia, stressing the importance of early detection and innovative therapies. Additionally, disparities in health outcomes for populations such as those with sickle cell disease (SCD) have come to the forefront.
The top 5 most-read articles related to rare blood disorders in 2024.
Image Credit: angellodeco - stock.Adobe.Com
Read more about 2024's top 5 most-read articles related to rare blood disorders.
5. Managing Rare Thrombotic Events Following COVID-19 Vaccination
This year, research has highlighted the importance of early identification and treatment of rare hematologic events, such as VITT and ITP, following COVID-19 vaccination. Investigators reviewed 9 cases of new-onset thrombocytopenia occurring 4 to 42 days post vaccination with Pfizer-BioNTech, Moderna, or AstraZeneca vaccines. Findings exhibited the role of diagnostic tests for heparin-induced thrombocytopenia (HIT) like HIT serotonin release assay in confirming VITT. They outlined treatment approaches, including corticosteroids, nonheparin anticoagulation, and intravenous immunoglobulin. Long-term outcomes varied, with some patients requiring prolonged hospitalization and complex interventions. Most patients continued with subsequent mRNA vaccinations, although the study acknowledged the need for more research into the ongoing management of VITT and ITP, particularly in refractory cases.
Read the full article.
4. Myeloid Panel Analysis Imperative for Risk Assessment in Patients With CCUS
Mutational analysis for patients with clonal cytopenia of undetermined significance (CCUS) who have undergone bone marrow examinations was supported by data from the Lancet Haematology. Findings suggested that identifying mutation profiles and high-risk mutations can better predict disease progression and enable earlier interventions. Researchers conducted a prospective study of over 2000 patients, revealing that 41.1% carried somatic mutations. Patients with CCUS were found to have distinct genetic mutations, such as TET2 and SRSF2, while mutations like SF3B1 and ASXL1 were more common in those progressing to myelodysplastic syndrome. The number of mutations can significantly predict progression to myeloid malignancies, with certain mutations, including TP53 and ASXL1, linked to worse survival outcomes, supporting the need for early detection and expanded genetic panels to optimize patient management.
Read the full article.
3. FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
In October, the first subcutaneous therapy for hemophilia B was approved by the FDA, offering a significant advancement in bleeding prevention for patients with hemophilia A or B without inhibitors. Marstacimab (Hympavzi) reduces the treatment burden of frequent intravenous infusions via weekly administration with its autoinjected pen. The therapy effectively decreased annualized bleeding rates by 35% compared with routine prophylaxis and 92% compared with on-demand treatment, based on phase 3 BASIS trial results. Developed by Pfizer, marstacimab targets the tissue factor pathway inhibitor to improve clotting and is priced at $795,600 annually, comparable to other hemophilia therapies. Experts and advocacy groups have praised the therapy for its potential to enhance quality of life.
Read the full article.
2. Immunosuppressive Therapies Shown to Significantly Impact Remission in Acquired Hemophilia A
Immunosuppressive therapies (ISTs) demonstrated efficacy in achieving complete remission (CR) in patients with acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing antibodies against factor VIII (FVIII). The investigation, involving 165 patients, revealed that IST, particularly rituximab-based regimens, achieved CR rates up to 93.3%, with bleeding controlled in over 80% of cases using hemostatic therapies like prothrombin complex concentrate or recombinant activated FVII. However, higher FVIII inhibitor titers (≥ 15 BU/mL) and bleeding scores of 6 or more were linked to poorer IST responses, emphasizing their prognostic value. Despite AHA's rarity and diagnostic challenges, the findings exhibit the potential of IST in managing AHA and call for larger, multicenter studies to refine treatment approaches and improve outcomes.
Read the full article.
1. COVID-19 Vaccination Rates Far Lower in Patients With SCD Compared With General Population
COVID-19 vaccination completion rates among patients with SCD were found to be significantly lower than those without SCD, with only 33.5% of SCD patients completing their vaccinations compared with over 61% of the general population. The research findings exhibit the increased vulnerability to severe infections of patients with SCD due to the disease's effects on the immune system, particularly concerning the spleen's function. Researchers analyzed data from the Michigan Care Improvement Registry and the Michigan Sickle Cell Data Collection program, identifying a total of 3424 individuals with SCD. The vaccination rates increased with age for both groups, and significant age-related differences in immunization completion were noted. The study stated the need for further research to understand vaccination perspectives among this population and to develop strategies to improve their vaccination rates to reduce COVID-19–related morbidity and mortality.
Read the full article.
A Place In The Sun's Laura Hamilton Gives Update On Potentially Fatal Autoimmune Disease
Laura Hamilton, has given an honest insight into how she's coping with a potentially fatal autoimmune diseaseA Place In The Sun star, Laura Hamilton, has given an honest insight into how she's coping with a potentially fatal autoimmune disease.
The 42-year-old presenter has Immune thrombocytopenic purpura (ITP), a rare blood disorder that results in low platelet levels, often causing excessive bruising.
Laura, has spoken openly about living with ITP and has now shared a snapshot of her bruised legs, giving insight into her daily struggle with the disease. While filming for A Place In The Sun in Greece on Monday, she revealed she's been experiencing 'flare-ups' this week and has resorted to wearing long dresses to conceal the bruising during shoots.
Laura Hamilton took to Instagram to update her followers about her ongoing battle with a rare autoimmune disease Her legs look badly bruised, but the presenter insisted that those with ITP shouldn't let it hold them backAlongside a photo of her heavily bruised leg, she penned: "This is ITP! Just a little flare-up this week. But you won't see it under my dress for filming! #itp #autoimmune #itpawareness".
In a video message, she expressed her gratitude to those who reached out after seeing her bruised legs, explaining: "So that's ITP, Immune thrombocytopenic purpura. It's a reaction from a low platelet count that I have in my blood. It's been a very, very crazy week for me which I'll tell you more about very soon. I've been really really busy and I think it's just taken its toll."
She captioned the video: "Also sorry to hear from those of you that have ITP too, particularly those whose children have it... I am happy to offer any advice that I can! Laura x."
Laura first spoke about her condition in October 2022, explaining that her ITP flares up when she's stressed. She recalled: "It was really mad a year ago I was filming A Place In The Sun with a lovely couple in France - Mark and Janine - and I just stood there and I had an insect bite on my leg and I started scratching it.
"I thought, 'Oh, I shouldn't have done that because I'm gonna have bruises on my leg from ITP.'" Laura continued: "Mark stopped and was like 'how do you know what ITP is? ' And he told me that really sadly his sister had died from ITP and he said it was really good how I was trying to raise awareness of it."
According to the NHS, fatal bleeding with ITP is rare and occurs more frequently in elderly patients and in those with severe thrombocytopenia.
Telling fans her ITP was "under control" Laura continued: "It's kind of under control at the moment, I don't have bruising quite like that on my legs, but it does happen, it does flare up, but I'm always trying to be positive about it. The disease only affects 4000 adults at one time, and is most common among young women." Explaining that the ITP also makes her gums bleed, she added: "I have had bruising on my arms and my gums have been bleeding."
However, the inspirational mum-of-two insisted those living with the condition shouldn't let it hold them back, concluding: "If you are an ITP sufferer my thoughts are with you. Don't let it get you down. Follow your dreams. Anything is possible. There is no need to let it hold you back... "
WHATSAPP GROUP: Be first to get the juiciest celebrity news to your phone by joining our Celebs WhatsApp here. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice. NEWSLETTER: Or sign up to the Mirror's Celebs newsletter here for all the biggest showbiz scandals, tell-all interviews and exclusive pictures straight to your inbox.Follow Mirror Celebs on TikTok , Snapchat , Instagram , Twitter , Facebook , YouTube and Threads .
Boosting Platelet Production
Cite this articleWei, A., Jackson, S. Boosting platelet production. Nat Med 14, 917–918 (2008). Https://doi.Org/10.1038/nm0908-917
Share this article Get shareable link
Comments
Post a Comment